PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
- Status
- COMPLETED
- Phase
- PHASE2
The Drug Rediscovery Protocol (DRUP Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
- Status
- COMPLETED
- Phase
- PHASE2
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
- Status
- COMPLETED
- Phase
- PHASE3
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1